Lucid Group (LCID) Calls Warrants on Cashless Basis
by Nicholas Alan Clayton on 2021-09-08 at 2:44pm

The Lucid Group (NASDAQ:LCID) announced that it will redeem all outstanding warrants at a price of $0.01 per Warrant at 5 pm EST October 8, and the warrants may be exercised on a cashless basis until then.

Doing this on a cashless basis means that warrantholders will not put out $11.50 and receive Class A shares proportionate to their warrant holdings. Instead, warrantholders are to pay the $11.50 per warrant exercise price by surrendering 0.5542 of a Class A share per warrant. In doing so, each exercised warrant will provide 0.4458 of a Class A share.

This ratio was determined in accordance with the warrant agreement and was based on the difference between the average share sale price for the two weeks prior to September 2 – $20.751 – and the original $11.50 exercise price.

The market has reacted to the news accordingly with Lucid slipping -3.6% in afternoon trading. Lucid warrants have similarly traded up about 1% to $8.50, just under the value of each warrant exercised in this cashless basis at the company’s current share price.

Lucid Motors has been the buzziest deal of the year since even before it announced its $11.75 billion combination with Churchill IV in February. Under the terms of the warrant agreement, Lucid was allowed to call its warrants once the company’s stock traded at or above $18 for 20 of 30 consecutive trading days.

And while Lucid could have called their warrants as early as August 26th (once the registration statement was declared effective and combination closing was more than 30 days prior), the PIPE investors were locked-up until September 1st.  As a result, Lucid Motors traded down ~ 31% on that date as PIPE investors came off lock-up and ahead of the warrant call.  And since the “20 out of 30 trading-day period” ends on the third trading day prior to when notice of redemption is given (Sept. 2), and since LCID would have certainly wanted to include Sept. 1st in it’s average sales price calculation for it’s ratio, calling the warrants today, September 8th, makes perfect sense.  Warrantholders might not like it, but LCID wanted to minimize dilution.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved